Company Quick10K Filing
Biorestorative Therapies
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 20 $5
10-Q 2019-11-13 Quarter: 2019-09-30
10-Q 2019-08-14 Quarter: 2019-06-30
S-1 2019-04-26 Public Filing
10-Q 2019-05-15 Quarter: 2019-03-31
10-K 2019-03-29 Annual: 2018-12-31
10-Q 2018-11-13 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-04-02 Annual: 2017-12-31
10-Q 2017-11-14 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-22 Annual: 2016-12-31
10-Q 2016-11-14 Quarter: 2016-09-30
10-Q 2016-08-15 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-23 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
10-Q 2015-05-15 Quarter: 2015-03-31
10-K 2015-03-31 Annual: 2014-12-31
10-Q 2014-11-13 Quarter: 2014-09-30
10-Q 2014-08-14 Quarter: 2014-06-30
10-Q 2014-05-14 Quarter: 2014-03-31
10-K 2014-04-11 Annual: 2013-12-31
10-Q 2013-11-19 Quarter: 2013-09-30
10-Q 2013-08-19 Quarter: 2013-06-30
10-Q 2013-05-15 Quarter: 2013-03-31
10-K 2013-04-02 Annual: 2012-12-31
10-Q 2012-11-05 Quarter: 2012-09-30
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-14 Quarter: 2012-03-31
10-K 2012-04-16 Annual: 2011-12-31
10-Q 2011-11-21 Quarter: 2011-09-30
10-Q 2011-08-17 Quarter: 2011-06-30
8-K 2020-02-20 Sale of Shares
8-K 2020-02-13 Regulation FD
8-K 2020-02-11 Sale of Shares, Regulation FD, Off-BS Arrangement, Exhibits
8-K 2020-02-03 Sale of Shares, Regulation FD
8-K 2020-01-27 Sale of Shares
8-K 2020-01-20 Sale of Shares
8-K 2020-01-10 Sale of Shares, Officers
8-K 2020-01-08 Sale of Shares, Officers, Shareholder Vote, Exhibits
8-K 2019-12-31 Sale of Shares
8-K 2019-12-19 Enter Agreement, Sale of Shares
8-K 2019-12-12 Sale of Shares
8-K 2019-12-02 Sale of Shares
8-K 2019-11-20 Sale of Shares
8-K 2019-11-13 Shareholder Vote, Exhibits
8-K 2019-11-01 Leave Agreement
8-K 2019-10-30 Sale of Shares
8-K 2019-10-16
8-K 2019-10-07 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-09-30 Sale of Shares
8-K 2019-08-30 Shareholder Vote, Regulation FD, Sale of Shares, Exhibits
8-K 2019-08-21 Sale of Shares
8-K 2019-07-26 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-07-11 Sale of Shares
8-K 2019-06-18 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-06-06 Sale of Shares
8-K 2019-05-30 Shareholder Vote, Exhibits
8-K 2019-05-22 Sale of Shares
8-K 2019-05-07 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-04-30 Regulation FD, Exhibits
8-K 2019-04-18 Sale of Shares
8-K 2019-02-19 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-02-06 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-01-22 Sale of Shares
8-K 2019-01-04 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-12-21 Sale of Shares
8-K 2018-12-13 Sale of Shares
8-K 2018-11-20 Enter Agreement
8-K 2018-10-28 Sale of Shares, Officers
8-K 2018-10-15 Enter Agreement, Officers, Exhibits
8-K 2018-10-04 Sale of Shares
8-K 2018-09-20 Sale of Shares
8-K 2018-09-06 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-08-31 Sale of Shares
8-K 2018-08-21 Shareholder Vote, Exhibits
8-K 2018-08-06 Sale of Shares
8-K 2018-06-27 Sale of Shares
8-K 2018-05-31 Regulation FD, Exhibits
8-K 2018-05-24 Regulation FD, Exhibits
8-K 2018-01-16 Officers, Regulation FD
8-K 2018-01-12 Sale of Shares

Biorestorative Therapies Financials

BRTX Metrics, Comps, Filings

Annual | Quarterly

Business

We were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from “Stem Cell Assurance, Inc.” to “BioRestorative Therapies, Inc.” Effective January 1, 2015, we reincorporated in Delaware.

In January 2017, we submitted an Investigational New Drug application to the U.S. Food and Drug Administration, or the FDA, to obtain authorization to commence a Phase 2 clinical trial investigating the use of BRTX-100, our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc disease. In February 2017, we received such authorization from the FDA.

In January 2019, a United States patent related to the ThermoStem Program was issued to us.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
E-Qure (EQUR) 4,836 -18.6 -215% 118 292 0 0 -254 -254 4,718
Sterling Consolidated (STCC) 4,728 31% 13.5 1% 7,036 5,715 7,564 2,328 53 347 4,695
Bespoke Extracts (BSPK) 4,647 71% 0.6 3,007% 227 93 54 39 6,825 7,274 4,533
Black Cactus Global (BLGI) 4,643 -1.2 -1,386% 286 916 0 0 -3,965 -3,900 4,601
Deep Well Oil & Gas (DWOG) 4,611 -21.7 -1% 22,677 527 0 0 -222 -211 4,577
Advantego (ADGO) 4,600 11% -5.2 -272% 554 4,782 29 3 -1,508 -858 4,465
Biorestorative Therapies (BRTX) 4,552 0% -0.2 -624% 2,432 11,375 60 0 -15,181 -14,961 3,470
Brightlane (BTLN) 4,486 79% -12.6 35,295,700% 100 79 -353 -353 4,449
Amplitech (AMPG) 4,468 54% 10.1 19% 1,810 717 2,660 1,447 342 415 4,190
Inception Mining (IMII) 4,468 -0.5 -727% 1,308 23,908 0 0 -9,511 -9,429 4,455
STR Holdings (STRI) 4,433 -36% -0.5 -37% 22,829 6,387 8,136 -2,910 -8,438 -9,407 4,738
Rodin Income Trust (RIT) 4,428 13.9 1% 25,840 17,277 0 0 298 298 4,133
Legacy Education Alliance (LEAI) 4,401 14% 0.9 -26% 27,535 76,570 90,706 12,769 -7,064 -6,234 -5,736
Artemis Therapeutics (ATMS) 4,380 -17.4 -661% 38 254 0 0 -251 -251 4,373
Globe Photos (GBPT) 4,374 4% -0.7 -33% 21,078 15,658 5,514 234 -6,876 -6,259 4,101
Greenkraft (GKIT) 4,344 50% -112.9 -2% 2,619 4,942 958 478 -39 -39 4,452
OWC Pharmaceutical Research (OWCP) 4,325 0% 3.9 27% 2,335 1,750 100 0 636 636 2,485
First Foods Group (FIFG) 4,309 0% -2.1 -479% 432 1,464 439 0 -2,070 -2,045 4,276
Wize Pharma (WIZP) 4,304 -0% -0.8 -115% 2,599 2,134 -2 0 -2,981 -2,981 2,509
True Nature Holding (TNTY) 4,298 -2.7 -701,080% 0 1,851 0 0 -1,991 -1,616 4,298

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-03-312015-12-312016-12-312017-06-302017-12-312018-12-312018-12-31
Cash72020192146167322452118118
Accounts Receivable93620382929
Inventory121822
PP&E9559177494537643509417328175175
Assets2211,2681,3831,6921,8582,0171,5801,4241,7591,1921,192
Accounts Payable4267711,2701,1121,2662,5492,2842,4672,4551,8941,894
Long-Term Debt3,5945248383302298120194524524
Liabilities3,9076,4108,0688,5809,2535,9256,5807,1398,5959,8339,833
Stockholders' Equity-3,686-5,142-6,685-6,888-7,395-3,908-5,000-5,715-6,837-8,641-8,641
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-03-312015-12-312016-12-312017-06-302017-12-312018-12-312018-12-31
Revenue01624166293681111111
Cost of Revenue1021426200
Gross Profit1412023673681
R&D124161,5941,4312,1052,8842,1521,5131,513
SG&A1,4771,3572,3802,3844,0393,3443,9694,3754,375
Tax000000
Net Income-4,074-6,537-5,751-5,588-7,923-8,636-9,445-12,518-12,518
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-03-312015-12-312016-12-312017-06-302017-12-312018-12-312018-12-31
Cash Operating-2,811-3,184-2,672-3,228-3,122-5,003-3,854-5,105-5,105
Cash Investing14-1,003-11-167-483-189-4-13-13
Cash Financing2,8504,1162,8843,2863,6805,0574,2774,7834,783